1. Home
  2. ILAG vs CVKD Comparison

ILAG vs CVKD Comparison

Compare ILAG & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intelligent Living Application Group Inc.

ILAG

Intelligent Living Application Group Inc.

HOLD

Current Price

$3.44

Market Cap

8.9M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$3.06

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ILAG
CVKD
Founded
1981
2022
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
10.3M
IPO Year
2020
2022

Fundamental Metrics

Financial Performance
Metric
ILAG
CVKD
Price
$3.44
$3.06
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
28.2K
71.7K
Earning Date
04-24-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.27
$3.02
52 Week High
$7.19
$14.64

Technical Indicators

Market Signals
Indicator
ILAG
CVKD
Relative Strength Index (RSI) 51.26 30.46
Support Level $0.44 N/A
Resistance Level $3.85 $5.99
Average True Range (ATR) 0.33 0.45
MACD -0.02 -0.07
Stochastic Oscillator 71.33 6.21

Price Performance

Historical Comparison
ILAG
CVKD

About ILAG Intelligent Living Application Group Inc.

Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Taiwan.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: